First Horizon Advisors’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.6K | Buy |
37
+18
| +95% | +$5.38K | ﹤0.01% | 1662 |
|
|
2025
Q1 | $5.86K | Hold |
19
| – | – | ﹤0.01% | 1771 |
|
|
2024
Q4 | $6.7K | Hold |
19
| – | – | ﹤0.01% | 1733 |
|
|
2024
Q3 | $6.81K | Sell |
19
-44
| -70% | -$14.9K | ﹤0.01% | 1727 |
|
|
2024
Q2 | $20.1K | Sell |
63
-2
| -3% | -$529 | ﹤0.01% | 1275 |
|
|
2024
Q1 | $14.9K | Buy |
65
+8
| +14% | +$1.8K | ﹤0.01% | 1452 |
|
|
2023
Q4 | $12.5K | Buy |
57
+19
| +50% | +$4.38K | ﹤0.01% | 1512 |
|
|
2023
Q3 | $8.58K | Buy |
38
+7
| +23% | +$1.61K | ﹤0.01% | 1574 |
|
|
2023
Q2 | $6.84K | Buy |
31
+27
| +675% | +$5.98K | ﹤0.01% | 1692 |
|
|
2023
Q1 | $895 | Hold |
4
| – | – | ﹤0.01% | 2287 |
|
|
2022
Q4 | $1.11K | Hold |
4
| – | – | ﹤0.01% | 2208 |
|
|
2022
Q3 | $0 | Sell |
4
-6
| -60% | -$1.34K | ﹤0.01% | 2473 |
|
|
2022
Q2 | $2K | Buy |
10
+8
| +400% | +$1.63K | ﹤0.01% | 2129 |
|
|
2022
Q1 | $0 | Sell |
2
-2
| -50% | -$381 | ﹤0.01% | 2285 |
|
|
2021
Q4 | $0 | Hold |
4
| – | – | ﹤0.01% | 2442 |
|
|
2021
Q3 | $0 | Buy |
+4
| New | +$788 | ﹤0.01% | 2432 |
|
|
2020
Q3 | – | Sell |
-132
| Closed | -$15K | – | 1540 |
|
|
2020
Q2 | $15K | Hold |
132
| – | – | ﹤0.01% | 901 |
|
|
2020
Q1 | $12K | Sell |
132
-12
| -8% | -$1.14K | ﹤0.01% | 900 |
|
|
2019
Q4 | $12K | Buy |
144
+12
| +9% | +$1.06K | ﹤0.01% | 1026 |
|
|
2019
Q3 | $10K | Hold |
132
| – | – | ﹤0.01% | 1082 |
|
|
2019
Q2 | $10K | Hold |
132
| – | – | ﹤0.01% | 1090 |
|
|
2019
Q1 | $15K | Hold |
132
| – | – | ﹤0.01% | 927 |
|
|
2018
Q4 | $14K | Hold |
132
| – | – | ﹤0.01% | 923 |
|
|
2018
Q3 | $16K | Sell |
132
-137
| -51% | -$16.9K | ﹤0.01% | 958 |
|
|
2018
Q2 | $29K | Buy |
269
+47
| +21% | +$5.17K | ﹤0.01% | 764 |
|
|
2018
Q1 | $24K | Hold |
222
| – | – | ﹤0.01% | 744 |
|
|
2017
Q4 | $32K | Hold |
222
| – | – | ﹤0.01% | 664 |
|
|
2017
Q3 | $26K | Hold |
222
| – | – | ﹤0.01% | 698 |
|
|
2017
Q2 | $27K | Hold |
222
| – | – | ﹤0.01% | 673 |
|
|
2017
Q1 | $27K | Sell |
222
-71
| -24% | -$10.8K | ﹤0.01% | 721 |
|
|
2016
Q4 | $33K | Hold |
293
| – | – | ﹤0.01% | 658 |
|
|
2016
Q3 | $33K | Buy |
293
+134
| +84% | +$16.1K | ﹤0.01% | 652 |
|
|
2016
Q2 | $16K | Sell |
159
-16
| -9% | -$1.78K | ﹤0.01% | 825 |
|
|
2016
Q1 | $19K | Buy |
175
+16
| +10% | +$2.02K | ﹤0.01% | 818 |
|
|
2015
Q4 | $24K | Sell |
159
-60
| -27% | -$8.73K | ﹤0.01% | 679 |
|
|
2015
Q3 | $28K | Hold |
219
| – | – | ﹤0.01% | 688 |
|
|
2015
Q2 | $38K | Buy |
219
+3
| +1% | +$540 | 0.01% | 619 |
|
|
2015
Q1 | $38K | Sell |
216
-63
| -23% | -$9.61K | 0.01% | 634 |
|
|
2014
Q4 | $36K | Sell |
279
-169
| -38% | -$21.8K | 0.01% | 637 |
|
|
2014
Q3 | $57K | Sell |
448
-21
| -4% | -$2.17K | 0.01% | 497 |
|
|
2014
Q2 | $41K | Buy |
469
+120
| +34% | +$11.5K | 0.01% | 607 |
|
|
2014
Q1 | $34K | Sell |
349
-151
| -30% | -$15.4K | ﹤0.01% | 614 |
|
|
2013
Q4 | $51K | Buy |
500
+110
| +28% | +$9.92K | 0.01% | 482 |
|
|
2013
Q3 | $31K | Sell |
390
-24
| -6% | -$1.75K | 0.01% | 557 |
|
|
2013
Q2 | $27K | Buy |
+414
| New | +$26.7K | 0.01% | 306 |
|
Other funds holding UTHR
ACA
First Horizon Advisors's UTHR Position: Q2 2025 in Review
First Horizon Advisors increased its United Therapeutics (UTHR) stake by 95% in Q2 2025, buying an estimated $5.38K and bringing the position to 37 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1662.
First Horizon Advisors first reported a position in UTHR in Q2 2013 and has held it in 45 quarters since. The position peaked at $57K in Q3 2014. 670 funds tracked by Wall St. Rank hold UTHR as of Q2 2025.
- First Horizon Advisors held 37 shares of United Therapeutics worth $10.6K as of Q2 2025.
- First Horizon Advisors bought 18 United Therapeutics shares in Q2 2025, an estimated $5.38K.
- United Therapeutics made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1662 holding.
- First Horizon Advisors first reported a position in United Therapeutics in Q2 2013 and has held it in 45 quarters since.
- First Horizon Advisors's United Therapeutics position peaked at $57K in Q3 2014.
- 670 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2025.
Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.